Related Experiment Video
Updated: Mar 9, 2026
Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
Published on: July 17, 2012
Development of a self-assembling aggregation-induced emission nanoprobe for targeted therapy and real-time imaging in
Zhen Ren1, Shuai Li2, Tong Cui2
1Central Hospital of Dalian University of Technology, Dalian, Liaoning, China; Faculty of Medicine, Dalian University of Technology, Dalian, Liaoning, China.
Abstract:
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide, characterized by poor prognosis and high relapse rates due to the limited therapeutic efficacy and tumor specificity of existing treatments. In this study, we developed a novel self-assembling aggregation-induced emission (AIE)-based nanomaterial (AIEnp) designed to target c-Met, a receptor tyrosine kinase that plays a critical role in tumor progression and resistance in NSCLC. The AIEnp system exhibits dual functionality: it enables fluorescence tracing for real-time imaging and provides targeted c-Met inhibition for therapeutic intervention. In vitro experiments demonstrated that AIEnp significantly reduced the viability of A549 lung adenocarcinoma cells in a concentration-dependent manner, while exhibiting minimal cytotoxicity toward HEK293T somatic cells. Mechanistically, AIEnp downregulated c-Met expression and its downstream signaling pathways, including FAK, MAPK, RAF, and STAT, thereby effectively disrupting multiple oncogenic cascades. The AIE-based design facilitated tumor-specific accumulation and fluorescence tracing, addressing the limitations of poor tumor penetration and non-specific distribution commonly observed in conventional therapies. These findings suggest that AIEnp represents a promising multifunctional platform for NSCLC treatment, combining targeted therapy with real-time imaging capabilities. Future studies will focus on in vivo validation and exploring the potential of AIEnps in combination therapies to further enhance their clinical applicability.
Insights
A new nanomaterial targets c-Met in non-small cell lung cancer (NSCLC), offering real-time imaging and effective tumor cell reduction. This approach improves treatment specificity and efficacy for NSCLC patients.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Non-small cell lung cancer (NSCLC) presents significant mortality and relapse challenges due to limited treatment efficacy and specificity.
- Targeting receptor tyrosine kinases like c-Met is crucial for overcoming tumor progression and resistance in NSCLC.
Purpose of the Study:
- To develop a novel aggregation-induced emission (AIE)-based nanomaterial (AIEnp) for targeted non-small cell lung cancer therapy.
- To investigate the dual functionality of AIEnp for fluorescence tracing and c-Met inhibition.
- To evaluate the efficacy and specificity of AIEnp in vitro.
Main Methods:
- Development of a self-assembling AIE-based nanomaterial (AIEnp) engineered to target c-Met.
- In vitro assessment of AIEnp cytotoxicity on A549 lung adenocarcinoma and HEK293T cells.
- Analysis of AIEnp's effect on c-Met expression and downstream signaling pathways (FAK, MAPK, RAF, STAT).
Main Results:
- AIEnp demonstrated significant, concentration-dependent reduction in A549 cell viability with minimal toxicity to HEK293T cells.
- AIEnp effectively downregulated c-Met expression and key oncogenic signaling pathways.
- The AIE design enabled tumor-specific accumulation and fluorescence tracing, overcoming conventional therapy limitations.
Conclusions:
- AIEnp is a promising multifunctional platform for non-small cell lung cancer treatment, combining targeted therapy with real-time imaging.
- The nanomaterial's ability to disrupt multiple oncogenic cascades offers a novel therapeutic strategy.
- Further in vivo studies are warranted to validate AIEnp's clinical applicability, including combination therapies.
